The biotech company, BeiGene Ltd., has made several significant strides in the cancer research field and in its corporate structure. The firm recently completed a re-domicilation to Switzerland and underwent a corporate name change to BeOne Medicines. BeiGene showed positive results in the stock market with consistent earnings growth and healthy outlook in shareholder returns.
BeiGene, now BeOne Medicines, continues to push boundaries in cancer drug research, presenting new findings at the RBC Capital Markets Global Healthcare Conference and at ASCO 2025. Notable progress includes a positive CHMP opinion for its drug TEVIMBRA®, a first-line treatment for nasopharyngeal cancer and successful phase 3 trials for other therapies.
Critically, the firm has shown financial progression with the successful sale of Amgen Imdlletra royalties to Royalty Pharma for $950 million, underpinning a new chapter in its growth trajectory.
Last but not least, BeiGene won a significant patent challenge against Pharmacyclics, survived accusations of theft of cancer therapy secrets from rival AbbVie, and announced a global licensing agreement for a MAT2A inhibitor.
BeiGene, Ltd. News Analytics from Mon, 11 Jan 2021 08:00:00 GMT to Fri, 23 Jan 2026 14:15:59 GMT - Rating 8 - Innovation 7 - Information 9 - Rumor 5
